Artboard 11

TAmiRNA presenting miND® NextGen sequencing opportunities at ISSX/DMDG 2023 Meeting

TAmiRNA will be a significant contributor to the inaugural joint European meeting of the ISSX and DMDG respectively focused on xenobiotics and drug metabolics.

Dr. Matthias Hackl, CEO and co-founder, will take part in the discussions of Symposium 4: ‘MicroRNAs as Biomarkers of Clinical Drug-induced Organ Injury’ (Tuesday, June 13, 1000-1200 hrs). Dr. Hackl’s presentation ‘miRNA Biomarker Development: Pitfalls and Best Practices for Discovery and Validation’ will highlight the increasing scope to apply TAmiRNA’s recently developed MicroRNA Next-Generation Sequencing Discovery (miND®) technology and associated miND® spike-ins to identify novel circulating microRNA biomarkers of CNS and other organ damage, as well as comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs).

Take advantage, meet Matthias and discuss our latest developments and how TAmiRNA’s miND spike ins and services can assist your business!

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.